• Neuralink has enrolled its first UK participant in the GB-PRIME study, marking the company's clinical trial expansion into Great Britain
  • The trial, conducted with University College London Hospitals and Newcastle Hospitals, aims to help patients with severe paralysis control devices using their thoughts
  • UK regulatory approval from the Medicines and Healthcare products Regulatory Agency positions the country as a growing hub for neurotechnology innovation

Neuralink has enrolled the first participant in the United Kingdom for its brain-computer interface clinical trial, accelerating the neurotechnology company's international expansion beyond its initial human trials in the United States.

The GB-PRIME study represents Neuralink's first clinical trial in Great Britain and is being conducted in collaboration with University College London Hospitals (UCLH) and Newcastle Hospitals. The trial has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) along with other ethical review boards, according to people familiar with the matter.

A company spokesperson confirmed the enrollment but declined to provide specific details about the participant, citing privacy concerns. "We're excited to bring this technology to patients in the UK who could benefit from restored digital autonomy," the spokesperson said in a brief statement.

The trial focuses on patients with tetraplegia, spinal cord injury, or Motor Neurone Disease who will receive Neuralink's proprietary N1 device. The implant records brain signals and enables participants to control external devices through thought alone, potentially offering new communication capabilities for those with severe paralysis.

This expansion comes as Neuralink continues to build momentum following its initial human trials in the US, where the company has implanted devices in over eight patients since beginning human testing in 2024. The UK participant represents the first step in what could become a broader European rollout, though regulatory hurdles remain significant across the continent.

Medical professionals involved in the trial see potential for meaningful impact. "This technology could represent a significant step forward for patients with limited communication options," said one clinician familiar with the program, who spoke on condition of anonymity because they were not authorized to discuss the trial publicly.

The UK's regulatory environment appears increasingly favorable for neurotechnology innovation, with the MHRA establishing clearer pathways for medical device approvals in recent years. This regulatory stability has attracted several neurotechnology companies to conduct trials in the country, though Neuralink represents one of the highest-profile entries into the UK market.

Neuralink's international expansion strategy now includes active trials in the US, UK, and Canada, positioning the Elon Musk-founded company at the forefront of the rapidly evolving brain-computer interface landscape. The company continues to recruit additional participants for its UK trials, though the exact timeline for further enrollments remains unclear.

Efforts to reach representatives from UCLH and Newcastle Hospitals for additional comment were not immediately successful. The hospitals have previously emphasized their commitment to cutting-edge neurological research in public statements.

Correction: An earlier version of this article misstated the number of US participants. Neuralink has implanted devices in over eight patients in the US, not ten.